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Adding aromatase inhibitors (AIs) to adjuvant treatment of post-
menopausal women with hormone-receptor–positive breast can-
cer significantly reduces cancer recurrence. A common side effect
of AIs is noninflammatory joint pain and stiffness (arthralgia) sim-
ilar to arthritis symptoms. An evidence-based walking program
developed by the Arthritis Foundation — Walk With Ease (WWE)
— reduces arthritis-related joint symptoms. We hypothesized that
WWE may also reduce AI-associated arthralgia. However, the po-
tential for different barriers and facilitators to physical activity for
these 2 patient populations suggested a need to adapt WWE be-
fore testing it with breast cancer survivors. We conducted qualitat-
ive research with 46 breast cancer survivors to explore program
modification and inform the development of materials for an adap-
ted program (Walk With Ease-Breast Cancer). Our process paral-
lels the National Cancer Institute’s Research-Tested Intervention
Programs (RTIPs) guidelines for adapting evidence-based pro-
grams for cancer populations. Findings resulted in a customized 8-
page brochure to supplement existing WWE materials.
Introduction
In 2014, an estimated 232,670 women in the United States re-
ceived a breast cancer diagnosis (1). Most cancers will be dia-
gnosed in postmenopausal women at an early, highly treatable
stage, and most tumors will be hormone receptor–positive (2,3).
For women with this tumor type, standard adjuvant (postsurgery
chemotherapy and/or radiation) treatment generally includes an
aromatase inhibitor (AI) to reduce the chances for cancer recur-
rence (4,5). Third generation AIs — exemestane (Aromasin), let-
rozole (Femara), and anastrozole (Arimidex) — are pills taken
daily for 5 years, with ongoing scientific consideration of addi-
tional years (4,5). Musculoskeletal symptoms — noninflammat-
ory joint pain, stiffness, or achiness (arthralgia) — are common
side effects of AIs, with an estimated 33% to 61% of women re-
porting these symptoms (6–9). When joint symptoms are moder-
ate or severe, they interfere with engagement in physical activity,
reduce overall quality of life, and can lead to AI discontinuation or
not taking the AI dose as prescribed (7,9,10).
The number of women who are likely to experience these symp-
toms is substantial. In 2012, there were an estimated 2.97 million
female breast cancer survivors, 75% of whom had tumors dia-
gnosed as being hormone receptor–positive;  most of these pa-
tients were likely to have been prescribed an AI (10). In an aging
US population — and breast  cancer being largely a disease of
aging with 61 years the median age at diagnosis (1) — the num-
ber of survivors coping with AI-associated arthralgia will contin-
ue to grow. Their quality of life and ability to be physically active
during adjuvant treatment may depend on the development of ef-
fective behavioral interventions to reduce these musculoskeletal
symptoms.
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Because AI-associated arthralgia symptoms are similar to those
caused by arthritis, we hypothesized that a physical activity pro-
gram developed by the Arthritis Foundation — Walk With Ease
(WWE) (11–14) — could have similar benefits for women on AI
therapy. However, the potential for unique psychosocial or medic-
al concerns warranted an investigation of the need to adapt WWE
for breast cancer survivors. We describe our process for develop-
ing and pilot testing materials to adapt WWE as a precursor to
program testing in a randomized controlled trial (currently under
way). Our adaptation process parallels guidelines developed by the
National Cancer Institute’s (NCI’s) Research-Tested Intervention
Programs (RTIPs) (15). We offer this description of our adapta-
tion process as an example of how evidence-based physical activ-
ity interventions developed for 1 patient population can be adap-
ted for a new patient population.
Background
Walk With Ease (WWE). WWE is a 6-week physical activity pro-
gram  that  is  evidence-based  in  both  group  and  self-directed
formats (13). In the interest of testing a program with potential for
scalability in clinic settings, we selected the self-directed format
for adaptation because it does not entail special facilities, equip-
ment, or personnel. Self-directed WWE is grounded in the social
cognitive theory constructs of self-efficacy and outcome expecta-
tions (17,18), which are important to encouraging exercise among
women with a breast cancer diagnosis (19). Accordingly, the 178-
page WWE workbook (Walk With Ease: Your Guide to Walking
for Better Health, Improved Fitness and Less Pain) (11) includes
chapters explaining how walking can reduce joint pain; offering
practical advice on how to start and stay motivated to exercise on a
daily basis; and providing tools such as self-tests, contracts, and
diaries. The goal in WWE is 150 cumulative minutes a week of
moderate-intensity walking or the equivalent of 30 minutes a day,
5 days a week.
NCI’s Research-Tested Interventions Programs (RTIPs). RTIPs is
a portal for program planners and public health practitioners that
facilitates access to research-tested interventions and program ma-
terials (15). The site includes a searchable database of 150 evid-
ence-based interventions focused on various health-related topics,
populations, and settings. To facilitate a systematic approach to
program adaptation, the site includes a section called Using What
Works: Adapting Evidence-Based Programs to Fit Your Needs
that provides learning modules and adaptation guidelines. The Ta-
ble lists the RTIPs 9-step process for guideline adaptation. Our
own adaptation  process  parallels  the  guidelines  developed by
RTIPs using a series of iterative steps, with step 9 under way in an
ongoing randomized controlled efficacy trial.
Methods
Semistructured interviews lasting no more than 30 minutes were
conducted in a sample of breast cancer survivors, primarily by
telephone. Study participants also completed questionnaire items
regarding  their  demographics  and  medical  history.  All  parti-
cipants provided written informed consent. The study protocol was
approved by the UNC Lineberger Comprehensive Cancer Center
Protocol Review Committee and the University of North Carolina
(UNC) at Chapel Hill Institutional Review Board.
Our adaptation process was conducted with breast cancer surviv-
ors recruited for 2 separate studies (Box) through clinics at the
North  Carolina  Cancer  Hospital.  The  median  age  in  our  final
sample (N = 46) was 67 years (range, 46–87), most were white
(90.5%), and 29% had a high school diploma or less education.
Fifty-nine percent  had self-reported arthritis.  For  study 1,  our
sample was limited to women aged 65 or older; for study 2, the
age limit was lowered to 21 or older. Inclusion criteria for both
studies were 1) stage I, II, or III breast cancer diagnosis, 2) cur-
rently on AI therapy, 3) self-reported joint pain, stiffness, or achi-
ness that is more than mild, 4) engaged in less than 150 minutes of
physical activity a week, 5) able to engage in moderate-intensity
physical activity, and 6) English speaking. We inquired whether
their joint symptoms were recent or of increased intensity in order
to identify survivors whose pain, stiffness, or achiness was most
likely to be associated with taking an AI.
Box. Flowchart for Study 1 and Study 2
Study 1: Breast cancer survivors on aromatase inhibitor
aged 65 or older
Sample 1: Formative (N = 10)
Interviews only, no walking•
Development of 2-page flyer Walk With Ease for Women with
Breast Cancer on Aromatase Inhibitor (AI) Therapy
•
Sample 2: Pilot test (N = 20)
6-Week walking program•
Postwalking interviews•
Study 2: Breast cancer survivors on aromatase inhibitor
aged 21 or older
Sample 3: Formative (N = 16)
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Development of 12-page brochure•
Prewalking interviews•
Refinement of 12-page brochure•
6-Week walking program•
Postwalking interviews•
Finalization of 12-page brochure•
The interview team consisted of the interviewer, note taker, and,
depending on their availability, patient advisors and other mem-
bers of the research team. Immediately following each interview,
interview notes were typed up by the note taker, which were re-
viewed and edited by others who participated in the interview.
Typed interview notes were analyzed by 3 research team mem-
bers; they independently identified themes in the data using them-
atic analysis, which shares with grounded theory an emphasis on
identifying themes that are grounded in the data (20–22). This ap-
proach allowed for identification of meaningful themes directly
representing participants’ experiences and feedback, without a pri-
ori assumptions about those themes. After these initial analyses,
team members met to review their findings and inductively derive
overarching themes and subthemes across all  interview topics.
Disagreements were resolved through group discussion to gain
consensus.
Adaptation Process
In our adaptation process (Table), several RTIPs steps are com-
bined, reflecting how the process actually flowed when implemen-
ted under the real-world conditions of  formative and pre–post
evaluation in 2 sequential studies.
Step 1
The first step is a determination of the needs of the intended audi-
ence and whether  the  program addresses  those needs.  Our  re-
search team includes expertise in oncology, rheumatology, physic-
al activity, qualitative research methodology, health promotion,
and intervention research. The team also includes 2 breast cancer
survivors who are currently taking an AI (our study’s patient ad-
visors) as well as consultants providing additional expertise in in-
tervention research focused on cancer patients and survivors. The
team reviewed the WWE workbook (11) for tone and content rel-
evance to breast cancer survivors experiencing AI-associated joint
symptoms and determined that there was a need to explore wheth-
er and how WWE should be adapted for our new patient popula-
tion.
Steps 2, 3, 4, and 7
In our iterative adaption process, several RTIPs steps were re-
peated with sequential groups of patients: 1) review the program
and its materials with the intended audience for feedback on ap-
propriateness, 2) define the extent of adaptation needed and poten-
tial ways to implement the new program, 3) develop mock-up ver-
sions of the adapted products, and 4) modify and revise the adap-
ted program and products based on pilot feedback. Completing
these steps through 3 sequential samples of survivors (Box) en-
abled us to conduct a recursive insights-gathering process about
participant needs for information and motivational strategies at
each  juncture  and whether  larger  changes  were  needed in  the
WWE program itself.
For  study 1/sample  1,  10  survivors  aged 65 or  older  were  re-
cruited for a general discussion of 1) likes and dislikes regarding
walking for exercise and enjoyment, potential benefits of walking,
and challenges or barriers to walking on a regular basis; 2) initial
thoughts regarding the WWE program (eg, the goal of 150 accu-
mulated minutes of walking per week, self-directed to let parti-
cipants determine their own pace at goal achievement); and 3) spe-
cific motivations for breast cancer survivors to consider a walking
program to reduce their joint symptoms. Content analysis of find-
ings from these formative interviews revealed participants’ desire
for supplementary information specific to potential musculoskelet-
al side effects of AIs and how moderate physical activity might re-
duce these side effects. Results of this discussion precipitated the
team’s development of a 2-page informational flyer titled Walk
With Ease for Women With Breast Cancer on Aromatase Inhibit-
or Therapy. Adhering to the self-directed WWE’s basis in social
cognitive theory, the flyer’s content was focused on self-efficacy
and outcome expectations: 1) general benefits of physical activity
for cancer patients and survivors (less fatigue, improved body im-
age, less depression and anxiety, fewer sleep problems, overall im-
proved health and quality of life), 2) potential AI therapy side ef-
fects of new or more severe joint pain, and 3) brief overview of
the WWE program and how it might relieve their joint symptoms.
In addition, participant quotes on the potential benefits of walking,
their own motivations to try a walking program, and motivational
thoughts for other breast cancer survivors were compiled into a 1-
page flyer (Breast Cancer Survivor Perspectives on Walking for
Pleasure or Exercise). Interview findings also prompted the inclu-
sion of a 6-week walking diary, as both a motivational tool and an
additional record of self-reported walking to measure participant
adherence to the 6-week walking program.
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For study 1/sample 2, a new sample of 20 survivors aged 65 or
older were recruited and interviewed after they had completed the
walking program to see whether there were additional or different
barriers or facilitators to doing the walking program after they had
experienced it. Participants received the 2-page informational fly-
er, 6-week walking diary, 1-page flyer of quotes, and WWE work-
book. They were interviewed about their overall experience with
the walking program and views on the 2-page flyer (tone and con-
tent) and were asked to identify motivational messages that they
thought were the most helpful. They were also asked who would
be the most effective person for advising or recommending that
breast cancer survivors engage in walking (eg, oncologist or onco-
logy clinical personnel, general practitioner), and they were asked
about strategies for encouraging breast cancer survivors to be-
come or stay physically active (eg, walking in a group, contact
from a professional counselor or breast cancer survivor, methods
such as telephone calls, emails, texts, or blogs). Content analyses
of findings from these formative interviews precipitated an expan-
sion of the original 2-page flyer into a brochure. Because some
participants were confused about “aromatase inhibitor therapy”
(they thought that their adjuvant medication was hormone treat-
ment and that AI therapy referred to something new), the title was
changed to Walk With Ease for Women with a Breast Cancer Dia-
gnosis (WWE-BC). The new brochure included additional quotes
from study participants, summarized findings from the pilot study
(20), and concluded with a 1-page “My Walking Plan” as an addi-
tional motivational tool (walking start date, walking goals, reas-
ons for walking, best days and times to walk, walking buddies,
and “what I will tell myself to stay motivated on days when walk-
ing  is  hard”).  The  ensuing  12-page  brochure  (developed with
desktop publishing software) included inspirational photos of di-
verse women and had an easy-to-read type size. Although the ac-
tual walking experience of sample 2 participants varied (20), inter-
view responses were supportive of our overall approach, which
asked women to achieve 150 minutes per week over 6 weeks; the
respondents also indicated that the overall program was safe, feas-
ible, and enjoyable.
For study 2/sample 3, 16 survivors from a wide age range — 21 or
older — were recruited and interviewed both before and after the
walking program. Prior topics were revisited to see if any new in-
formation and themes would emerge from this cohort. We asked
about 1) participants’ knowledge of AI side effects before receiv-
ing the study materials and learning about the objectives of the
study,  2)  the value of  having a discussion with the oncologist
about AI side effects and engaging in moderate physical activity to
reduce joint symptoms, and 3) their advice on methods for encour-
aging survivors to attempt and sustain a walking routine. There
were no new findings regarding the WWE-BC materials or pro-
gram; however, there were many findings to inform a future dis-
semination and implementation study. In addition, findings led us
to edit the brochure into a tighter 8-page format that is being tested
in our ongoing randomized controlled trial (RCT).
Step 5
RTIPs guidelines recommend working with expert advisors to en-
sure the adapted products maintain the accuracy of the originals.
Two members of the research team (L.F.C. and M.A.) were prin-
cipal investigator and co-investigator for a study funded by the
Centers for Disease Control and Prevention to adapt the group
format of WWE to a self-directed format and conduct a 2-group
effectiveness test with a large sample of community-based adults
(12–14). They ensured that while adaptation modifications made
clarifications for breast cancer survivors, the intervention content
remained true to the original WWE health education, exercise, and
motivational tool core components.
Step 6
RTIPs guidelines recommend pilot testing with representatives
from the target audience. The initial adaptation of the program was
pilot tested with study 1/sample 2 breast cancer survivors aged 65
or older. The program was found to be feasible (walking minutes
increased between baseline and 6 weeks), safe (no adverse events),
and showed promising effects on joint stiffness (20). In postwalk-
ing semistructured interviews, participants reported that the pro-
gram’s emphasis on walking safely and comfortably and achiev-
ing the goal of 150 minutes at each participant’s own pace made
WWE-BC enjoyable  and realistic,  even for  women who were
largely sedentary.
Steps 8 and 9
The final 2 steps pertain to implementing the adapted program and
evaluating its effectiveness. WWE-BC is still in the efficacy test-
ing phase through an ongoing RCT. In the event findings from the
RCT are positive, plans include effectiveness testing in an imple-
mentation study.
Discussion
We describe the adaptation of an evidence-based arthritis program
for a new patient population — breast cancer survivors on AI ther-
apy who are experiencing joint symptoms. Our adaptation process
paralleled guidelines recommended by NCI’s RTIPs. We found
that the RTIPs guidelines are realistic and practical to implement
in a real-world context and that they serve as a helpful checklist to
ensure that program adaptation is conducted systematically and
thoroughly.
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The materials we developed to adapt the WWE arthritis program
were reviewed and revised through an iterative process involving
46 breast cancer survivors as well as our patient advisors and out-
side consultants. A limitation of our study is our largely white and
well-educated sample, which is not representative of the larger
population of breast cancer survivors. However, our interviews did
not  reveal  differences  in  perspectives  or  informational  needs
between white survivors and survivors of other races. It is an em-
pirical question whether responses from a more diverse sample
would have substantially changed our findings.
Our adaptations were confined to essential new information, read-
ability, wording, quotes, photos, and ways to reach our target audi-
ence. The underlying theory, targeted health behavior, timeline,
dosage, and core components remained unchanged, and no new
strategies were added that would detract from the core compon-
ents. This description of our adaptation strategies and process may
be informative for others seeking systematic guidance for adapt-
ing, implementing, and testing evidence-based physical activity in-
terventions for cancer patients and survivors.
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Table
Table. Overview of Walk With Ease Adaptation Process Guided by NCI’s RTIPs Guidelines
NCI’s RTIPs Guideline Adaptation Processes
Step 1: Determine the needs of your audience
and whether the program addresses those
needs.
Research teama reviewed WWE workbook for tone and content relevance to breast
cancer survivors on aromatase inhibitor therapy who are experiencing joint
symptoms.
Step 2: Review the program and its materials
with your intended audience for feedback on its
appropriateness.
Semistructured interviews focusing on content needs and material adaptation
conducted with breast cancer survivors before and/or after reviewing WWE and WWE-
BC materials and doing the walking program (study 1/sample 1 and study 1/sample
2).
Step 3: Define the extent of adaptation needed
and potential ways to implement the new
program.
Research teama, patient advisors, and consultants to the research team reviewed
findings from the interviews.
Step 4: Develop “mock-up” versions of the
adapted products.
Adapted products produced: 2-page flyer; 12-page brochure; 8-page brochure; 8-page
brochure with walking diary attached.
Step 5: Work with expert advisors to ensure
that the adapted products maintain the
accuracy of the originals.
Expert review by authors L.F.C. and M.A., who were leaders in the study funded by the
Centers for Disease Control and Prevention to adapt the group format of WWE to a
self-directed format and to conduct a 2-group effectiveness test.
Step 6: Pilot test the adaptation with
representatives from your audience.
Pilot tested in survivors aged 65 or older (study 1; results presented elsewhere
[20]).
•
Pilot tested further in survivors aged 21 or older (study 2/sample 3). Satisfaction
with adapted materials investigated through interviews.
•
Step 7: Modify and revise the adapted program
and products based on pilot feedback.
WWE-BC flyer and brochures were modified after each round of interviews.
Step 8: Implement the program. NA
Step 9: Evaluate the effectiveness of your
adapted program and products.
Ongoing NCI-funded randomized controlled trial to test program and product
effectiveness.
Abbreviations: NA, not applicable; NCI RTIPs, National Cancer Institute’s Research-Tested Intervention Programs (http://rtips.cancer.gov/rtips/
index.do); WWE, Walk With Ease (evidence-based physical activity program offered by the Arthritis Foundation); WWE-BC, Walk With Ease for Women
With a Breast Cancer Diagnosis.
a The research team includes members with expertise in oncology, rheumatology, qualitative research methodology, and intervention research. The
team also includes 2 breast cancer survivors who are currently taking an AI and consultants providing additional expertise in intervention research fo-
cused on cancer patients and survivors.
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